Zevra Therapeutics Q2 2024 GAAP EPS $(0.48) Misses $(0.44) Estimate, Sales $4.449M Beat $4.412M Estimate
Portfolio Pulse from Benzinga Newsdesk
Zevra Therapeutics (NASDAQ:ZVRA) reported Q2 2024 GAAP EPS of $(0.48), missing the $(0.44) estimate, and sales of $4.449M, beating the $4.412M estimate. EPS decreased by 500% year-over-year, while sales decreased by 47.47%.
August 13, 2024 | 8:12 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Zevra Therapeutics reported Q2 2024 GAAP EPS of $(0.48), missing the $(0.44) estimate, and sales of $4.449M, beating the $4.412M estimate. EPS decreased by 500% year-over-year, while sales decreased by 47.47%.
The significant miss on EPS and the large year-over-year decrease in both EPS and sales are likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100